Infinium Pharmachem Limited is a prominent pharmaceutical company incorporated on November 21, 2003, initially as a private limited company. The company converted to a public limited company in August 2022 and successfully completed its public offering of 18,75,000 equity shares, raising ₹25.25 crore in April 2023.
Founded by Sanjaykumar Viththalbhai Patel, Pravin Bhadabhai Madhani, and others, the company has established itself as a globally recognized manufacturer and exporter of iodine-based pharmaceutical products. With over a decade of rich experience, Infinium has built a strong reputation in the specialty chemicals and pharmaceutical intermediates sector.
Infinium Pharmachem specializes in the development, manufacturing, and export of iodine derivatives used across multiple industries. The company currently maintains a portfolio of 250+ intermediates and 15+ APIs, making it one of the leading suppliers in the iodine chemistry space. The company's portfolio includes approximately 200+ Iodine Derivatives and seven+ APIs, manufacturing and supplying a range of Iodine based APIs on an Order to Make basis.
The company serves diverse industries including pharmaceutical, chemical, biotech, and allied industries across the globe. It has extended its services into multiple sectors such as Pharmaceutical, Biotech, Specialty, Performance Chemicals, Agrochemicals, Human and Animal Health, Cosmetics, Sanitation, and Electrical Electronics.
Infinium provides contract Research and Manufacturing Services (CRAMS) to pharmaceutical and biotech companies for their diverse requirements of Iodine based APIs and intermediates, aiming to reduce their research time and project costs. The technical expertise of their R&D team enables them to provide fully integrated and customized Contract Research and Manufacturing services.
The company operates from its state-of-the-art manufacturing facility located at 38 GIDC Sojitra, Taluka-Sojitra, Anand, Gujarat-387240. The manufacturing facility is fully equipped, ISO 9001 Certified, FDA Approved, and GMP Compliant to match industry quality standards. The company is GMP Compliant, FDA, ISO-9001, and ISO-14001 certified, ensuring adherence to the highest international standards.
The facility has been audited by various well-known pharma giants worldwide, demonstrating its commitment to quality and regulatory compliance. The company provides full A-Z vendor documents support to meet stringent regulatory compliance requirements for filing documents with various authorities for pharma companies.
Infinium has pursued strategic expansion through joint ventures and subsidiaries. In 2019, the company formed a Joint Venture with Shanghai Witofly Chemical Co. Ltd., named Shanghai Tajilin Industrial Co. Ltd., in the People's Republic of China. The company also established a subsidiary called Infinium Green Energy Private Limited in June 2022, indicating its diversification into renewable energy sectors.
Infinium Pharmachem demonstrates strong financial metrics. The company has an operating revenue of Rs. 394.35 Cr. on a trailing 12-month basis. An annual revenue growth of 19% is outstanding, with a pre-tax margin of 11% and a Return on Equity (ROE) of 19%.
The company is debt-free and has a strong balance sheet, enabling it to report stable earnings growth across business cycles. Recent performance shows robust financial results with sales up 24%, EBITDA up 112%, and net profit up 61%.
#### Key Financial Metrics:
• Market Cap: ₹431.65 Crore (as of July 2025)
• 52-week high: ₹392.50
• 52-week low: ₹178.05
• P/E ratio: 42.02
• Promoter holding: 65.24% (as of November 2024)
As a responsible Corporate Citizen, Infinium Pharmachem undertakes a number of CSR activities in the larger interest of the community, especially in the area of children's needs and development, education, environment, and local needs. The company is committed to behaving ethically and contributing to economic development while improving the quality of life for its workforce and their families, as well as for the local community and society at large.
Infinium maintains a strong global presence through its export operations. The company ensures that products reach customers safely and on time, with expertise in handling hazardous and non-hazardous shipments across the world. The company regularly participates in major international pharmaceutical exhibitions, including CPHI Europe, CPHI China, and CPHI India, demonstrating its commitment to global market expansion.
With its specialized focus on iodine chemistry, comprehensive product portfolio, strong manufacturing capabilities, and commitment to quality, Infinium Pharmachem Limited is well-positioned to capitalize on the growing demand for specialty pharmaceutical intermediates and APIs in both domestic and international markets.
